Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.2002.99.202 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Liposomal Formulation of an Organogold Complex Enhancing Its Activity as Antimelanoma Agent-In Vitro and In Vivo Studies.
Pharmaceutics
December 2024
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal.
The therapeutic management of melanoma, the most aggressive form of skin cancer, remains challenging. In the search for more effective therapeutic options, metal-based complexes are being investigated for their anticancer properties. Cisplatin was the first clinically approved platinum-based drug and, based on its success, other metals (e.
View Article and Find Full Text PDFSynergistic combination effect of the PCA-1/ALKBH3 inhibitor HUHS015 on prostate cancer drugs in vitro and in vivo.
Anticancer Drugs
January 2025
Department of Pharmacy, Laboratory of Chemical Biology, Advanced Medicinal Research Center, Hyogo Medical University, Kobe.
Prostate cancer antigen-1/ALKBH3, a DNA/RNA demethylase of 3-methylcytosine, 1-methyladenine (1-meA), and 6-meA, was found in prostate cancer as an important prognostic factor. Additionally, 1-meA has been associated with other cancers. The ALKBH3 inhibitor HUHS015 was found to be effective against prostate cancer both in vitro and in vivo .
View Article and Find Full Text PDFCharacteristics of long-survivor metastatic melanoma after polychemotherapy and interferon: a retrospective study.
Swiss Med Wkly
December 2023
Department of Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
Background: The development of immunotherapy and tyrosine kinase inhibitors dramatically improved the prognosis of metastatic melanoma. Consequently, chemotherapy is now rarely used. Here, we describe the characteristics of long-surviving patients with metastatic melanoma treated with immunochemotherapy.
View Article and Find Full Text PDFComplexity of diagnosing and treating langerhans cell sarcoma: A case report.
Tunis Med
July 2023
Hematology Department, Hedi Chaker Hospital of Sfax, Tunisia.
Introduction: Langerhans cell sarcoma (LCS) is a very rare malignant tumor of Langerhans cells that may metastasize to many organs. The diagnosis of this tumor is difficult and its prognosis is poor.
Aim: To report the difficulty to diagnose LCS, and discuss therapeutic management of this rare entity.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!